Parse Medical | Consultancy services for Medical Affairs and Medical Communications

Tag: #MedComms

  • Communicating the safety profile of an oncology drug

    —

    by

    parsemedical
    in

    At the centre of any communication on the adverse event (AE) profile of a new drug lies a fundamental principle: no medication is ever completely safe. Every drug, from over-the-counter paracetamol to cutting-edge biologics, is associated with a specific set of AEs listed on the package insert. Having said that, anticancer drugs exist in a…

  • On the power of clinical cases in medical education

    —

    by

    parsemedical
    in ,

    Why do we so frequently use clinical case scenarios in satellite symposia? There’s a short and a long answer to this question. The short answer is: ‘Because they are engaging’. Yes, it’s as simple as that – the real-world* clinical cases will keep your audience’s attention for as long as the discussion continues. (* or…

  • Medical insights: Workshop-based training for your field team

    —

    by

    parsemedical
    in ,

    While medical science liaisons (MSLs) are great at building relationships and gathering information, do you sometimes wish they would be better in translating the intelligence obtained in the field into meaningful medical insights that can inform your global strategy? You are not alone! Many Global Medical Affairs professionals recognise the importance of regular training of…

  • Medical Education: Learning objectives

    —

    by

    parsemedical
    in

    📢 One of the key responsibilities of Medical Affairs departments in pharma is to communicate medical value of the company’s products through medical education. 🎨 It can take a variety of forms, from infographics and information leaflets, to scientific and educational sessions at an international meeting. In fact, because the learning tools are endless, so…

  • Therapy area expertise

    —

    by

    parsemedical
    in

    💡 All medical writers list therapy area expertise in their CV and portfolio, but how do we know that we have achieved true expertise? The standard response probably revolves around treatment guidelines, FDA/EMA approvals ✅ and clinical data 📈 of pivotal Phase 3 studies. However, personally, I found that additional knowledge is what marks you…